{
    "ticker": "ACXP",
    "name": "Acasti Pharma Inc.",
    "description": "Acasti Pharma Inc. is a biopharmaceutical company focused on the development of innovative prescription drugs for the treatment of cardiovascular and metabolic diseases. Founded in 2002 and based in Laval, Quebec, Acasti is known for its lead product candidate, CaPre\u00ae, a prescription medication derived from krill oil, which is being developed to treat severe hypertriglyceridemia. The company leverages its proprietary technology and extensive research to create products that can provide significant improvements in patient outcomes. Acasti is committed to addressing unmet medical needs related to cardiovascular health and aims to be a leader in the emerging field of omega-3-based therapeutics. In addition to CaPre\u00ae, the company continues to explore other indications and formulations that can further enhance its product pipeline. Acasti Pharma is driven by a mission to transform the lives of patients through effective and safe therapeutic options while maintaining a strong emphasis on scientific rigor and regulatory compliance.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Laval, Quebec, Canada",
    "founded": "2002",
    "website": "https://www.acastipharma.com",
    "ceo": "Jan D. H. Vandenbrande",
    "social_media": {
        "twitter": "https://twitter.com/AcastiPharma",
        "linkedin": "https://www.linkedin.com/company/acasti-pharma"
    },
    "investor_relations": "https://www.acastipharma.com/investor-relations",
    "key_executives": [
        {
            "name": "Jan D. H. Vandenbrande",
            "position": "CEO"
        },
        {
            "name": "Pierre Lemieux",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Prescription Drugs",
            "products": [
                "CaPre\u00ae"
            ]
        }
    ],
    "seo": {
        "meta_title": "Acasti Pharma Inc. | Innovative Cardiovascular Therapeutics",
        "meta_description": "Explore Acasti Pharma Inc., a biopharmaceutical company dedicated to developing novel therapies for cardiovascular and metabolic diseases. Learn about their innovative product pipeline and commitment to patient care.",
        "keywords": [
            "Acasti Pharma",
            "CaPre",
            "Cardiovascular Health",
            "Biopharmaceuticals",
            "Hypertriglyceridemia"
        ]
    },
    "faq": [
        {
            "question": "What is Acasti Pharma known for?",
            "answer": "Acasti Pharma is known for its development of CaPre\u00ae, an omega-3 prescription medication for treating severe hypertriglyceridemia."
        },
        {
            "question": "Who is the CEO of Acasti Pharma?",
            "answer": "Jan D. H. Vandenbrande is the CEO of Acasti Pharma Inc."
        },
        {
            "question": "Where is Acasti Pharma headquartered?",
            "answer": "Acasti Pharma is headquartered in Laval, Quebec, Canada."
        },
        {
            "question": "What are Acasti Pharma's main products?",
            "answer": "Acasti Pharma's main product is CaPre\u00ae, aimed at treating hypertriglyceridemia."
        },
        {
            "question": "When was Acasti Pharma founded?",
            "answer": "Acasti Pharma was founded in 2002."
        }
    ],
    "competitors": [
        "AMRN",
        "CVAC",
        "PFE"
    ],
    "related_stocks": [
        "JNJ",
        "MRK",
        "ABBV",
        "GILD"
    ]
}